Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 “SLC34A2” in Papillary Thyroid Carcinoma: An Immunohistochemical Study

Table 2

Relationship between SLC34A2 IHC expression and clinicopathological characteristics.

		SLC34A2				value	Significance
		Low		High
Age group	<55	56	45.9%	66	54.1%	≤0.001	HS
	≥55	19	16.4%	97	83.6%
Gender	Male	8	16.7%	40	83.3%	0.013	S
	Female	67	35.3%	123	64.7%
Lymph node at presentation	N0	54	32.9%	110	67.1%	0.484^‡	NS
	N1	21	28.4%	53	71.6%
Lymphovascular invasion	Negative	59	30.7%	133	69.3%	0.595^‡	NS
	Positive	16	34.8%	30	65.2%
Capsular invasion	Negative	69	54.3%	58	45.7%	≤0.001	HS
	Positive	6	5.4%	105	94.6%
PTC variants	Classic	54	31.4%	118	68.6%	0.988	NS
	Follicular	16	31.4%	35	68.6%
	Other	5	33.3%	10	66.7%
Extrathyroid extension	Negative	74	35.7%	133	64.3%	≤0.001	HS
	Positive	1	3.2%	30	96.8%
Stage	I	72	38.1%	117	61.9%	≤0.001	HS
	II	3	7.9%	35	92.1%
	III	0	0.0%	11	100.0%
Tumor size (cm)	≤4	62	54.4%	52	45.6%	≤0.001	HS
	>4	13	10.5%	111	89.5%

^‡Student’s -test. Chi-square test. Solute carrier family 34 member A2 (SLC34A2); immunohistochemical (IHC); papillary thyroid carcinoma (PTC); highly significant (HS); significant (S); not significant (NS).